-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KIN-3248 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KIN-3248 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KIN-3248 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Solid Tumor Drug Details: Tazemetostat hydrobromide (Tazverik)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab in Nasopharyngeal Cancer Drug Details: Bevacizumab (Avastin) is a recombinant humanized...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ciforadenant in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ciforadenant in Refractory Multiple Myeloma Drug Details: Ciforadenant is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXL-770 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PXL-770 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Drug Details: PXL-770 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s V-184
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Solarcentury Hldgs – Ak Kin Solar Park 99.99MW – Coahuila
Equip yourself with the essential tools needed to make informed and profitable decisions with our Solarcentury Hldgs - Ak Kin Solar Park 99.99MW - Coahuila report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Castlepoint NUMA/ Forthlane/ KIN Capital – 1800 Weston Mixed-Use Tower – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our Castlepoint NUMA/ Forthlane/ KIN Capital - 1800 Weston Mixed-Use Tower - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
Castlepoint NUMA/ Forthlane/ KIN Capital – 1830 Weston Mixed-Use Development – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our Castlepoint NUMA/ Forthlane/ KIN Capital - 1830 Weston Mixed-Use Development - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...